Medicine and Dentistry
Patient
100%
Major Bleeding
68%
Therapeutic Procedure
67%
Venous Thromboembolism
62%
Rivaroxaban
58%
Blood Clotting Factor 10a Inhibitor
47%
Age
36%
Pulmonary Embolism
35%
Analysis
34%
Anticoagulation
22%
Clinical Trial
20%
Bleeding
18%
Hemostat
17%
Post-Hoc Analysis
17%
Blood Stasis
16%
Arm
15%
Child
15%
Atrial Fibrillation
15%
Thrombosis
15%
Menorrhagia
15%
Blood Clot Lysis
15%
Chronic Kidney Disease
15%
Patient Selection
15%
Woman
15%
Kidney Function
15%
Cancer Treatment
15%
Sequela
15%
Vagina Bleeding
15%
Direct Oral Anticoagulant
15%
Anticoagulant
15%
Glomerular Filtration Rate
13%
Follow up
12%
Chronic Thromboembolic Pulmonary Hypertension
11%
Hazard Ratio
10%
Antithrombotic
9%
Hospital
8%
Deterioration
7%
Apixaban
7%
Acute Pulmonary Embolism
6%
Treatment Duration
6%
Embolism
5%
Apoplexy
5%
Anticoagulant Therapy
5%
Low Molecular Weight Heparin
5%
Pharmacology, Toxicology and Pharmaceutical Science
Fondaparinux
17%
Cohort Study
15%
Thrombin Inhibitor
15%
Direct Oral Anticoagulant
14%
Anticoagulation Therapy
11%
